Navigation Links
Aegera Therapeutics Reports Survival Data from the Phase 1 Portion of its Phase 1-2 Study of AEG35156 in Combination with Sorafenib in Patients with Advanced Hepatocellular Carcinoma
Date:7/19/2010

tion and now focused on completing recruitment to the randomized Phase 2 portion of the clinical trial to confirm the therapeutic benefit of the AEG35156/sorafenib combination" stated Professor Benny Chung-Ying Zee, PhD, Director of the Centre for Clinical Trials, School of Public Health and Primary Care, Faculty of Medicine, The Chinese University of Hong Kong.

For more information of the study please refers to the following trial registration: http://clinicaltrials.gov/ct2/show/NCT00882869

About AEG35156

AEG35156 is a 2nd generation antisense oligonucleotide which targets XIAP; it is designed to lower the apoptotic threshold of cancer cells, enhancing their sensitivity to intrinsic death and chemotherapy, without harming healthy cells. Patients are also being currently enrolled in a Phase 1/2 monotherapy study in CLL/indolent B-cell lymphomas, which is fully funded by The Leukemia and Lymphoma Society of North America.

About Aegera Therapeutics Inc.

Aegera Therapeutics is a clinical stage biotechnology company focused on developing novel targeted therapies that address major unmet medical needs. In addition to AEG35156, Aegera is working with its partner Human Genome Sciences (NASDAQ:HGSI) to progress HGS1029 through early stage clinical development for oncology and is also actively working on several preclinical programs in the area of autoimmune, inflammatory and central nervous system diseases. Additional information on these programs can be found on Aegera's website at '/>"/>

SOURCE AEGERA THERAPEUTICS INC.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Aegera Therapeutics phase 1/2 clinical trial results selected for oral presentation at 2008 ASH Annual Meeting
2. Aegera Therapeutics Initiates A Randomized Phase 2 Combination Study of AEG35156 for 1st Line Treatment of Non-Small Cell Lung Cancer
3. Aegera Initiates Phase 2 Clinical Trial Of AEG33773 - A Small Molecule Targeting Neuropathic Pain
4. Aegera Therapeutics Initiates a Randomized Phase 2 Study with AEG35156 for the Treatment of Hepatocellular Carcinoma
5. Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leukemia (AML)
6. Halozyme Therapeutics Reports 2008 Second Quarter Financial Results
7. Repair Stem Cell Institute Announces Industrys First Standards of Excellence for Global Stem Cell Treatment Centers to Protect Patients from Less-than-Competent Therapeutics
8. Amsterdam Molecular Therapeutics Reports Half Year Results 2008
9. BN ImmunoTherapeutics Announces Partnership With National Cancer Institute
10. Arno Therapeutics Announces Appointment of Brian Lenz, CPA as Chief Financial Officer
11. CV Therapeutics Announces Ranexa(R) Named Finalist for Prix Galien USA 2008 Award
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... New York (PRWEB) July 25, 2014 ... Market Research, "Biological Drugs Market - Global Industry Analysis, ... the global biological drugs market is estimated at USD ... at a CAGR of 10.1% from 2014 to 2020, ... in 2020. , The biological drugs market is witnessing ...
(Date:7/25/2014)... , July 25, 2014 /PRNewswire-iReach/ -- Xybion ... consulting for global corporations operating in highly regulated ... its first annual Global User Group Conference, Xybion ... Philadelphia, Pennsylvania at the ... http://photos.prnewswire.com/prnh/20140724/130263 This year,s ...
(Date:7/24/2014)... 2014 Gain recognition for leadership ... of the biotech industry. Nominations are now being ... to you by the Bio Supply Management ... chain management professionals for the past 7 years. ... the Biotech industry – Manufacturers, Service Providers, Material ...
(Date:7/24/2014)... team led by group leader Yung-Eun Sung has ... synthesize sulfur-doped and nitrogen-doped graphenes which can be ... and fuel cells. Yung-Eun Sung is both a ... at Institute for Basic Science* (IBS) and a ... achievement has great significance with regards to the ...
Breaking Biology Technology:Biological Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Biological Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3Xybion Announces It Will Host International User Conference in Philadelphia 2Xybion Announces It Will Host International User Conference in Philadelphia 3Call for Submission: BSMA’s Supply Chain Management Innovation Awards 2Call for Submission: BSMA’s Supply Chain Management Innovation Awards 3
... Reaches severance agreement with unionsSEATTLE, May 15 Cell ... that, as previously discussed in a press release on ... operations and has reached agreement with the employee union ... a reduction of CTI,s total headcount in Italy by ...
... (TSX:ONC, NASDAQ: ONCY ) announced today that data from ... at the 2009 American Society of Clinical Oncology (ASCO) Annual ... 29-June 2, 2009. The abstracts are available on the ASCO ... poster presentations, - Dr. Monica ...
... May 14 /PRNewswire-FirstCall/ - Spectral Diagnostics Inc., (TSX: SDI), ... and a therapeutic targeting severe sepsis, today announced its ... 2009. , "This quarter, we achieved an important milestone ... Toraymyxin(TM) for the US market after thorough due diligence ...
Cached Biology Technology:Cell Therapeutics Closes Italian Facility, Reduces Headcount and Expects to Cut $14 Million in Operating Expenses 2Oncolytics Biotech(R) Inc.'s Research Collaborators to Present Data on REOLYSIN(R) Clinical Trials at ASCO Conference 2Spectral announces first quarter 2009 results 2Spectral announces first quarter 2009 results 3Spectral announces first quarter 2009 results 4Spectral announces first quarter 2009 results 5Spectral announces first quarter 2009 results 6Spectral announces first quarter 2009 results 7
(Date:7/24/2014)... York, NY - July 24, 2014 -- Keryx Biopharmaceuticals, ... from the long-term, randomized, active control Phase 3 study ... iron-based phosphate binder, for the treatment of hyperphosphatemia in ... PERFECTED study (PhosphatE binding and iRon delivery with FErric ... Journal of the American Society of Nephrology ...
(Date:7/24/2014)... Bushmeat, the use of native animal species for food ... be a significant factor in the decline of many ... new study indicates that more than half of the ... raptors and hornbills., "By surveying not only the meat ... being eaten inside the forest by hunters and brought ...
(Date:7/24/2014)... study has identified two factors that characterize sustainable ... production of highly qualified physics teachers. Specifically, one ... physics teacher education in combination with institutional motivation ... viable. Science, Technology, Engineering and Math (STEM) teacher ... study points the way for institutions seeking to ...
Breaking Biology News(10 mins):Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4Creating sustainable STEM teacher preparation programs 2
... noses and Microsoft Windows, infamous blue screen of death ... being made by a new research report appearing online ... Specifically, scientists now know exactly why we sneeze, what ... not work properly. Much like a temperamental computer, our ...
... Olympic athletes may be the best trained and physically ... susceptible to back pain. BackPainRelief.net is releasing an infographic ... injuries can be avoided. (Photo: ... for a number of injuries, and back pain is ...
... (July 30, 2012) When the longest cells in the body ... is no easy task. This is in part because these ... one meter in adult humans which is a lot ... order to reach the "command center" of the cell,s nucleus. ...
Cached Biology News:Allergies? Your sneeze is a biological response to the nose's 'blue screen of death' 2Backpainrelief.net Tackles Sports Injuries with Infographic 2Long-distance distress signal from periphery of injured nerve cells begins with locally made protein 2Long-distance distress signal from periphery of injured nerve cells begins with locally made protein 3
... IndicationIncludes all the features of Tracker, plus software ... for a user defined period of time in ... a family of instruments all built around a ... and that can track two fields at once ...
... all features of Tracker, plus software to note ... and provide a food reward.The Spatial Behavior line ... a video camera, frame grabber, and feature extraction ... once and up to 6 moving animals. ...
... Place AvoidanceIncludes all features of Tracker, plus ... a user defined subsection of the arena, and ... family of instruments all built around a video ... that can track two fields at once and ...
tracking dye in electrophoresis; free acid, C 19 H 10 BrO 5 S; MW: 669.96...
Biology Products: